Rybelsus belongs to the drug class called glucagon-like peptide-1 (GLP-1) receptor agonists
Jimena Hathaway, MD, MPH, published in the Journal of the American Medical Association, indicates that Semaglutide, the active ingredient in Ozempic, Wegovy, and Rybelsus, shows an increased risk of vision loss
Semaglutide is a GLP-1 receptor agonist, available under the brand names Ozempic (for diabetes) and Wegovy (for weight loss)
Patients on semaglutide frequently report a reduction in perceived hunger, an earlier sense of fullness during meals, decreased attraction to calorie-dense foods, increased energy for physical activity, and improved blood pressure, cholesterol, and blood sugar metricsall indicating a potential for potent health benefits within weeks of starting on the regimen
Shapsis notes that patients whose primary goal is weight loss , and who qualify medically, typically achieve better and more predictable results with Wegovy